The gene sequencing industry is developing rapidly, and the second generation sequencing is the mainstream technology. At present, the first generation of gene sequencing technology can't meet the needs of research and application because of its low Qualcomm and long sequencing time. The second-generation sequencing technology characterized by low Qualcomm is the most widely used sequencing technology at present, and the sequencing time is much shorter than that of the first-generation technology. As an important part of precision medicine, gene sequencing has developed rapidly in recent years, from $794 million in 2007 to $4.5 billion in 20 13, with a compound growth rate of 33.5%. It is predicted that it will continue to grow rapidly in the next few years, reaching11700 million USD in 20 18 years.
The upstream of the industrial chain is dominated by European and American enterprises, while China enterprises are mainly concentrated in the sequencing service industry in the middle and lower reaches, and there is a trend of extending to the upstream. At present, China's gene sequencing enterprises are mainly concentrated in the sequencing service industry in the middle and lower reaches of the industrial chain, while the upstream gene sequencing equipment consumables suppliers have a high technical threshold and are basically monopolized by foreign-funded enterprises. Because the key technology of gene sequencing is still in the hands of European and American gene sequencing equipment and reagent consumables manufacturers represented by Illumina for a long time, China's gene testing industry has no complete pricing power and is subject to European and American enterprises everywhere. In order to change this situation, the industrial chain of China enterprises began to extend upstream.
The application market of gene sequencing is broad. At present, China is mainly divided into four directions. The clinical application of downstream gene sequencing approved by the US Food and Drug Administration in China can be divided into four categories, namely, genetic disease diagnosis, prenatal screening and diagnosis, preimplantation embryo genetic diagnosis and tumor diagnosis and treatment. Non-invasive prenatal screening is a mature product with the highest consumer recognition. With the liberalization of the second child policy in China, the market will have further room for growth. Cancer diagnosis and treatment is the most potential application market, and cancer has become the second leading cause of death in the world. With the arrival of China's aging society, the incidence of cancer in China will further increase, and the application of second-generation sequencing in tumor neighborhood will have great development potential.